Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hospital costs associated with adverse events in people with diabetes in the UK

Keng MJ. et al, (2022), Diabetes, Obesity and Metabolism

BEHRTDAY: Dynamic Mortality Risk Prediction using Time-Variant COVID-19 Patient Specific Trajectories

Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1

Using Shapes of COVID-19 Positive Patient-Specific Trajectories for Mortality Prediction

Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1

CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA

Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data

Wu R. et al, (2022), Value in Health, 25, S16 - S16

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group Writing Committee: None. et al, (2021), Eur Heart J

Benefits from optimised antihypertensive and statin treatment in high risk people

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 2728 - 2728

Load More

Handbooks in Health Economic Evaluation

A series published by Oxford University Press.